New code

COVID Vaccine Administration Codes

  • 0001A – Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage diluent reconstituted; first dose
  • 0002A – second dose
  • 0011A – …vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose
  • 0012A – second dose
  • 0021A – …vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAd0x1) vector, preservative free, 5×1010 viral particles/0.5 mL dosage; first dose
  • 0022A – second dose
  • 0031A – …vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage; first dose
  • 0034A – booster dose
  • 0041A – …vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose
  • 0042A – second dose
  • 0051A – Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage trissucrose formulation; first dose
  • 0052A – second dose
  • 0053A – third dose
  • 0054A – booster dose
  • 0064A – …vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage; booster dose
  • 0071A – …vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
  • 0072A – second dose

COVID Vaccine Codes

  • 91300 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
  • (Report 91300 with administration codes 0001A, 0002A)
  • 91301 – … vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
  • (Report 91301 with administration codes 0011A, 0012A)
  • 91302 – …vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1(ChAd0x1) vector, preservative free, 5×10 10 viral particle/0.5 mL dosage, for intramuscular use
  • (Report 91302 with administration codes 0021A, 0022A)
  • 91303 – DNA, spike protein, adenovirus type 26 (Ad 26) vector, preservative free, 5×10 10 viral particles/0.5 mL dosage, for intramuscular use
  • (Report 91303 with administration code 0031A)
  • 91304 – … recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use
  • (Report 91304 with administration codes 0041A, 0042A)
  • 91305– Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease
    [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose, for intramuscular use
  • (Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A)
  • 91306 – … vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
  • (Report 91306 with administration code 0064A)
  • 91307 – …vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL diluent reconstituted, tris-sucrose formulation, for intramuscular use
  • (Report 91307 with administration codes 0071A, 0072A)

COVID-19 Vaccines

CPT codes are developed as needed for the reporting of immunizations for the novel coronavirus (SARS-CoV-2).

The American Medical Association (AMA) has created a tool to help select the appropriate CPT® code for the type and dose of vaccine that is being administered.


Special editions of CPT ® Assistant also provide coding guidance such as full code descriptions, clinical examples, and FAQs.

COVID-19 CPT® Coding and Guidance

The AMA CPT Editorial Panel has developed CPT codes unique for each vaccine in addition to administration codes. To determine the appropriate CPT code to report, refer to the AMA tool “Find your COVID-19 Vaccine CPT® Codes”

The tool asks the following questions to determine which code or codes should be reported:

  1. “Do you know the vaccine manufacturer or brand name?” (Moderna, Pfizer, AstraZeneca, Novavax, or Janssen)
  2. “Which dose is being administered?” (first, second, third, single dose, booster)

AMA CPT Professional Edition- Appendix Q: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines The table in Appendix Q connects the individual COVID-19 vaccine codes) to their associated immunization administration codes, manufacturer name, vaccine name(s), 10 and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the Medicine section of the CPT code set.

In May 2021, it was announced by the Biden-Harris administration that the Health Resources and Services Administration COVID -19 Assistance Fund will cover the costs of administering COVID-19 vaccines to patients whose health insurance does not cover vaccine administration fees or is subject to cost-sharing.

ICD-10 CM Codes

The Centers for Disease Control and Prevention (CDC) has developed coding guidance for health care encounters and deaths related to the 2019 novel coronavirus (COVID-19). In certain circumstances, other codes for conditions not related to coronavirus may be required in accordance with the ICD-10-CM Official Guidelines for Coding and Reporting. A hyphen at the end of a code indicates an additional character is required.

Encounter for Screening
Z11.52- Encounter for screening for COVID-10

Exposure or Contact
Z20.822- Contact with and (suspected) exposure to COVID-19
Contact with and (suspected) exposure to SARS-CoV-2

Identified Coronavirus Infection
U07.1-COVID-19, virus identified
Use additional code to identify pneumonia or other manifestations, such as:
pneumonia due to COVID-19 (J12.82) Excludes2: coronavirus as the cause of diseases classified
elsewhere (B97.2-)
coronavirus infection, unspecified (B34.2)
pneumonia due to SARS-associated coronavirus (J12.81)
Report U07.1 if:
▪ The patient has a confirmed diagnosis of the 2019 novel coronavirus disease (COVID-19) as
documented by the provider;
▪ There is documentation of a positive COVID-19 test result; or ▪ A presumptive positive COVID-19 test result. A presumptive positive test result is defined as an “individual has tested positive for the virus at a local or state level, but it has not yet been confirmed by the Centers for Disease Control and Prevention (CDC).

If COVID is the principal diagnosis, it should be listed first and then followed by the appropriate codes for associated manifestations.

Do not report U071.1 if the providers documentation indicates the patient’s condition is “suspected,” “possible,” “probable,” or “inconclusive” COVID19. In that case, report a code(s) indicating the reason for encounter (ex. a fever) or Z20.828 (Contact with and (suspected) exposure to other viral communicable diseases).

Personal History

Z86.16- Personal history of COVID-19 (excludes post-COVID condition, see U09)

Provisional Assignment of New Diseases of Uncertain Etiology or Emergency Use
U09- Post COVID-19 condition
U09.9- Post COVID-10 condition, unspecified

ICD-10 CM code enables establishment of a link with COVID-19. It is not to be used in cases that are still presenting with active COVID-19. However, an exception is made in cases of reinfection with COVID-19, occurring with a condition related to prior COVID-19.